Evidence map›Paper›PMID 41636022›Full record

ReviewThe European journal of neuroscience2026

Glutamate Delta 1 Receptor in Synapses, Circuits, and Disease.

Diane Choi, Poojashree B Chettiar, Yoland Smith, Shashank M Dravid

Abstract readReview
In one paragraph

Review in The European journal of neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Glutamate Delta 1 Receptor in Synapses, Circuits, and Disease.The European journal of neuroscience · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Diane ChoiGraduate Program in Molecular and Systems Pharmacology, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-2326-5197
Poojashree B ChettiarDepartment of Psychiatry and Behavioral Science, Texas A&M University, College Station, Texas, USA.
Yoland SmithGraduate Program in Molecular and Systems Pharmacology, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-8700-878X
Shashank M DravidDepartment of Psychiatry and Behavioral Science, Texas A&M University, College Station, Texas, USA.ORCID 0000-0002-9912-8148

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Trans-synaptic signaling complex in amygdala pain mechanismsR01NS118731 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DRAVID, SHASHANK MANOHAR, NEUGEBAUER, VOLKER · 2020 to 2024
$2.7M
Striatal Trans-Synaptic Signaling Mechanism in ParkinsonismR01NS133338 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Hong-Yuan Chu, Shashank Manohar Dravid · 2024 to 2026
$2.0M
Function of glutamate delta-1 receptorR01MH116003 · NIMH · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DRAVID, SHASHANK MANOHAR · 2018 to 2022
$1.9M
Structure-Function and Signaling of Glutamate Delta 1 in Pain MechanismR21NS132590 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DRAVID, SHASHANK MANOHAR · 2023 to 2023
$404k
NIH HHS GM 8602-24NIH HHS P51 OD011132NIMH NIH HHS MH116003NIMH NIH HHS R01 MH116003NINDS NIH HHS NS118731NINDS NIH HHS NS132590NINDS NIH HHS NS133338NINDS NIH HHS R01 NS118731NINDS NIH HHS R01 NS133338NINDS NIH HHS R21 NS132590ORIP NIH HHS OD011132
6 · The paper itself

Abstract

The glutamate delta 1 receptor (GluD1) remained largely unexplored since its cloning three decades ago because it lacked typical ligand-gated ion channel activity. In the last decade, much progress has been made in identifying its potential function. This research has been greatly enhanced by the development of specific tools to determine receptor expression and distribution and genetic mouse models to explore region specific roles in regulating circuits and behavior. Major strides have also been taken in understanding the structure-function of the receptor. These studies demonstrate that GluD1 has many distinctive characteristics including synaptogenic activity at both excitatory and inhibitory synapses, the ability of the ligand-binding domain to bind not only D-serine but also GABA, its unique structural arrangement among the ionotropic glutamate receptor family in relation to domain swapping and the ability to induce tonic currents in the native system. Studies have also identified its role in regulating the postsynaptic content of AMPA and NMDA receptors and synaptic plasticity. Finally, human genetic studies revealed the relationship of GluD1 with neuropsychiatric disorders, including schizoaffective disorders and intellectual disability, which is consistent with the phenotypes observed in mice upon GluD1 ablation. The role of GluD1 is also becoming evident in neurological disorders, particularly chronic pain. Thus, GluD1 has quickly emerged as a receptor with multifaceted roles in physiology and pathology.

Indexed as

Mental DisordersReceptors, GlutamateSynapsesAnimalsHumansNeuronal Plasticityglutamate receptor delta 1Receptors, GlutamateD‐serineexpressionGABAGRID1mutations

Identifiers

PMID41636022
PMCPMC12869354

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.